Marketer: Tripada Healthcare Pvt. Ltd
(Bold for FDA approved)
• Theoretically reduces excitatory glutamate neurotransmission and increases inhibitory gamma-aminobutyric acid (GABA) neurotransmission
• Binds to and blocks certain glutamate receptors, including metabotropic glutamate receptors
• Because withdrawal of alcohol following chronic administration can lead to excessive glutamate activity and deficient GABA activity, acamprosate can act as “artificial alcohol” to mitigate these effects
• Has demonstrated efficacy in trials lasting between 13 and 52 weeks
• Diarrhea, nausea
• Anxiety, depression
• Suicidal ideation and behavior (suicidality)
unusual
unusual
• Wait
• Adjust dose
• If side effects persist, discontinue use
• 666 mg three times daily (>60 kg)
• 666 mg two times daily (<60 kg)
• Tablet 333 mg and 666mg
•Has been studied in trials up to 1 year
•No
• For moderate impairment, recommended dose is 333 mg three times daily
• Contraindicated in severe impairment
• Dose adjustment not generally necessary
• Limited data available
• Some patients may tolerate lower doses better
• Consider monitoring renal function
• Safety and efficacy have not been established
• Risk Category C [some animal studies show adverse effects; no controlled studies in humans]
• Pregnant women needing to stop drinking may consider behavioral therapy before pharmacotherapy
• Not generally recommended for use during pregnancy, especially during first trimester
• Unknown if acamprosate is secreted in human breast milk, but all psychotropics assumed to be secreted in breast milk
• Recommended either to discontinue drug or bottle feed
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera